{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T18:37:51Z","timestamp":1787337471248,"version":"build-2736575974"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T00:00:00Z","timestamp":1743811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T00:00:00Z","timestamp":1743811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Alma Mater Studiorum - Universit\u00e0 di Bologna"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To evaluate the role of PSMA PET\/CT-guided salvage radiotherapy (sRT) in improving long-term biochemical recurrence-free survival (bRFS) in patients with biochemical recurrence (BCR) or PSA persistence (PERS) after radical prostatectomy (RP) for localized prostate cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-center retrospective study included 100 patients with BCR or PERS after RP who underwent [\u2076\u2078Ga]Ga-PSMA-11 PET\/CT and sRT according to EAU guidelines. The primary endpoint was bRFS (PSA\u2009\u2264\u20090.2 ng\/ml).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Sixty-three patients had BCR and 37 had PERS. Fifteen patients had PSA pre-RT\u2009&lt;\u20090.5 ng\/ml, while 75 had PSA pre-RT\u2009\u2265\u20090.5 ng\/ml. [\u2076\u2078Ga]Ga-PSMA-11 PET\/CT was positive in 52 patients, with BCR patients more frequently exhibiting local recurrence while PERS patients showed more nodal involvement. Patients with PERS received sRT and androgen deprivation therapy (ADT) in 57% of cases. The hazard ratio (HR) of treatment failure for patients with PSA pre-RT\u2009\u2265\u20090.5 ng\/ml vs.\u2009&lt;\u20090.5 ng\/ml was 2.2 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.039). With a median follow-up of 59 months, treatment failure occurred in 36% of patients, with no difference between BCR and PERS groups. Among those with treatment failure, 64% were [\u2076\u2078Ga]Ga-PSMA-11 PET\/CT positive at recurrence, and 39% received a new PSMA PET\/CT-based RT. All patients were alive at the last analysis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>[\u2076\u2078Ga]Ga-PSMA-11 PET\/CT-guided sRT demonstrates significant long-term efficacy in patients with BCR or PERS after RP, leading to durable PSA response and guiding further treatment decisions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>244\/2016\/O\/Oss8 November 2016 retrospectively registered.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-025-07255-6","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T18:45:13Z","timestamp":1743878713000},"page":"3720-3729","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Long-term outcomes of PSMA PET\/CT-guided radiotherapy in biochemical failure patients post-radical prostatectomy: a 5-year follow-up analysis"],"prefix":"10.1007","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-3973-4409","authenticated-orcid":false,"given":"Andrea","family":"Di Giorgio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giambattista","family":"Siepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Serani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1729-9438","authenticated-orcid":false,"given":"Martina","family":"Di Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Malizia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Castellucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Fanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Farolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,5]]},"reference":[{"key":"7255_CR1","doi-asserted-by":"crossref","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024 May-Jun;74(3):229\u201363.","DOI":"10.3322\/caac.21834"},{"issue":"6","key":"7255_CR2","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.eururo.2020.02.009","volume":"77","author":"TJ Wilt","year":"2020","unstructured":"Wilt TJ, Vo TN, Langsetmo L, Dahm P, Wheeler T, Aronson WJ, Cooperberg MR, Taylor BC, Brawer MK. Radical prostatectomy or observation for clinically localized prostate cancer: extended Follow-up of the prostate cancer intervention versus observation trial (PIVOT). Eur Urol. 2020;77(6):713\u201324.","journal-title":"Eur Urol"},{"issue":"8","key":"7255_CR3","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1111\/j.1464-410X.2012.11012.x","volume":"110","author":"K Westover","year":"2012","unstructured":"Westover K, Chen MH, Moul J, Robertson C, Polascik T, Dosoretz D, Katin M, Salenius S, D\u2019Amico AV. Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer. BJU Int. 2012;110(8):1116\u201321.","journal-title":"BJU Int"},{"issue":"2","key":"7255_CR4","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","volume":"86","author":"D Tilki","year":"2024","unstructured":"Tilki D, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Part II-2024 update: treatment of relapsing and metastatic prostate cancer. Eur Urol. 2024;86(2):164\u201382.","journal-title":"Eur Urol"},{"issue":"6","key":"7255_CR5","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.eururo.2019.03.016","volume":"75","author":"D Tilki","year":"2019","unstructured":"Tilki D, Preisser F, Graefen M, Huland H, Pompe RS. External validation of the European association of urology biochemical recurrence risk groups to predict metastasis and mortality after radical prostatectomy in a European cohort. Eur Urol. 2019;75(6):896\u2013900.","journal-title":"Eur Urol"},{"key":"7255_CR6","doi-asserted-by":"crossref","unstructured":"Paller CJ, Antonarakis ES, Eisenberger MA, Carducci MA. Management of patients with biochemical recurrence after local therapy for prostate cancer. Hematol Oncol Clin North Am. 2013;27(6):1205-19, viii.","DOI":"10.1016\/j.hoc.2013.08.005"},{"issue":"13","key":"7255_CR7","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1002\/pros.24592","volume":"83","author":"A Gruen","year":"2023","unstructured":"Gruen A, Tegel K, Kluge A, Budach V, Zips D, Boehmer D. PSMA PET-based stereotactic body radiotherapy for locally recurrent prostate cancer after definitive first-line therapy. Prostate. 2023;83(13):1298\u2013305.","journal-title":"Prostate"},{"issue":"30","key":"7255_CR8","doi-asserted-by":"publisher","first-page":"3648","DOI":"10.1200\/JCO.2016.67.9647","volume":"34","author":"RD Tendulkar","year":"2016","unstructured":"Tendulkar RD, Agrawal S, Gao T, Efstathiou JA, Pisansky TM, Michalski JM, et al. Contemporary update of a Multi-Institutional predictive nomogram for salvage radiotherapy after radical prostatectomy. J Clin Oncol. 2016;34(30):3648\u201354.","journal-title":"J Clin Oncol"},{"key":"7255_CR9","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.3389\/fonc.2020.01359","volume":"10","author":"F Shaikh","year":"2020","unstructured":"Shaikh F, Dupont-Roettger D, Dehmeshki J, Kubassova O, Quraishi MI. Advanced imaging of biochemical recurrent prostate cancer with PET, MRI, and radiomics. Front Oncol. 2020;10:1359.","journal-title":"Front Oncol"},{"issue":"2","key":"7255_CR10","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00259-014-2949-6","volume":"42","author":"A Afshar-Oromieh","year":"2015","unstructured":"Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, et al. The diagnostic value of PET\/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42(2):197\u2013209.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7255_CR11","doi-asserted-by":"crossref","unstructured":"Hofman MS, Kasivisvanathan V, Link E, Buteau J, Roberts MJ, Francis RJ et al. Baseline nodal status on 68Ga-PSMA-11 positron emission tomography\/computed tomography in men with Intermediate- to High-risk prostate cancer is prognostic for treatment failure: Follow-up of the ProPSMA trial. Eur Urol Oncol. 2024 Nov 28:S2588-9311(24)00251-7.","DOI":"10.1016\/j.euo.2024.11.006"},{"issue":"5","key":"7255_CR12","doi-asserted-by":"publisher","first-page":"939","DOI":"10.3390\/cancers16050939","volume":"16","author":"H Al Saffar","year":"2024","unstructured":"Al Saffar H, Chen DC, Delgado C, Ingvar J, Hofman MS, Lawrentschuk N, et al. The current landscape of prostate-Specific membrane antigen (PSMA) imaging biomarkers for aggressive prostate cancer. Cancers (Basel). 2024;16(5):939.","journal-title":"Cancers (Basel)"},{"issue":"8","key":"7255_CR13","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1007\/s00259-023-06185-5","volume":"50","author":"N Solomonidou","year":"2023","unstructured":"Solomonidou N, Germanou D, Strouthos I, Karagiannis E, Farolfi A, Koerber SA, et al. PSMA-PET\/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA\u2009<\u20090.2 Ng\/ml. Eur J Nucl Med Mol Imaging. 2023;50(8):2529\u201336.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"7255_CR14","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13014-018-0983-4","volume":"13","author":"NS Schmidt-Hegemann","year":"2018","unstructured":"Schmidt-Hegemann NS, Fendler WP, Ilhan H, Herlemann A, Buchner A, Stief C, et al. Outcome after PSMA PET\/CT based radiotherapy in patients with biochemical persistence or recurrence after radical prostatectomy. Radiat Oncol. 2018;13(1):37.","journal-title":"Radiat Oncol"},{"key":"7255_CR15","doi-asserted-by":"publisher","first-page":"723536","DOI":"10.3389\/fonc.2021.723536","volume":"11","author":"NS Schmidt-Hegemann","year":"2021","unstructured":"Schmidt-Hegemann NS, Zamboglou C, Thamm R, Eze C, Kirste S, Spohn S, et al. A Multi-Institutional analysis of prostate cancer patients with or without 68Ga-PSMA PET\/CT prior to salvage radiotherapy of the prostatic fossa. Front Oncol. 2021;11:723536.","journal-title":"Front Oncol"},{"key":"7255_CR16","doi-asserted-by":"crossref","unstructured":"Zamboglou C, Staus P, Wolkewitz M, Peeken JC, Ferentinos K, Strouthos I et al. Better oncological outcomes after Prostate-specific membrane antigen positron emission Tomography-guided salvage radiotherapy following prostatectomy. Eur Urol Focus 2024 Nov 27:S2405-4569(24)00247-5.","DOI":"10.1016\/j.euf.2024.11.006"},{"issue":"5","key":"7255_CR17","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","volume":"83","author":"R Seifert","year":"2023","unstructured":"Seifert R, Emmett L, Rowe SP, Herrmann K, Hadaschik B, Calais J, et al. Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2). Eur Urol. 2023;83(5):405\u201312.","journal-title":"Eur Urol"},{"key":"7255_CR18","doi-asserted-by":"publisher","first-page":"1408752","DOI":"10.3389\/fonc.2024.1408752","volume":"14","author":"P Anderson","year":"2025","unstructured":"Anderson P, Dogan N, Ford JC, Padgett K, Simpson G, Stoyanova R, et al. Repeatability, reproducibility, and the effects of radiotherapy on radiomic features of lowfield MR-LINAC images of the prostate. Front Oncol. 2025;14:1408752.","journal-title":"Front Oncol"},{"issue":"1","key":"7255_CR19","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13014-024-02440-7","volume":"19","author":"A Zapatero","year":"2024","unstructured":"Zapatero A, Castro P, Roch M, Carnero PR, Carroceda S, Rosciupchin AES, et al. Functional imaging guided stereotactic ablative body radiotherapy (SABR) with focal dose escalation and bladder trigone sparing for intermediate and high-risk prostate cancer: study protocol for phase II Safo trial. Radiat Oncol. 2024;19(1):54.","journal-title":"Radiat Oncol"},{"issue":"2","key":"7255_CR20","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.euf.2020.12.009","volume":"7","author":"J Calais","year":"2021","unstructured":"Calais J, Armstrong WR, Kishan AU, Booker KM, Hope TA, Fendler WP, et al. Update from PSMA-SRT trial NCT03582774: A randomized phase 3 imaging trial of prostate-specific membrane antigen positron emission tomography for salvage radiation therapy for prostate cancer recurrence powered for clinical outcome. Eur Urol Focus. 2021;7(2):238\u201340.","journal-title":"Eur Urol Focus"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07255-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07255-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07255-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T10:15:24Z","timestamp":1757153724000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07255-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,5]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["7255"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07255-6","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,5]]},"assertion":[{"value":"31 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of IRCCS Azienda Ospedaliero-Unversitaria Policlinico S. Orsola di Bologna (244\/2016\/O\/Oss\u20148 November 2016).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Author Andrea Di Giorgio, Giambattista Siepe, Martina Di Franco, Claudio Malizia and Andrea Farolfi declare they have no financial interests. Paolo Castellucci received consulting fees, travel fees, or honoraria from Novartis, Curium, Recordati, Astra Zeneca. Stefano Fanti reports, outside the submitted work, personal honoraria from Novartis and personal fees from AAA, Amgen, Astellas, Bayer, Debio, GE Healthcare, Immedica, Janssen, Sofie, and Telix.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial interests"}}]}}